Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Gastroenterol Hepatol Retrieve available abstracts of 124 articles: HTML format

Single Articles

October 2023
1. DIBLEY L, Duffy M
   Inflammatory bowel disease health care for LGTBQIA+ patients.
   Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
   PubMed    
   
   
   
2. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
   Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
   Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
   PubMed     Abstract available
   
   
   
3. QUAN J, Markovinovic A, Hracs L, Ma C, et al
   Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
   Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
   PubMed    
   
   
   September 2023
4. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
   Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
   Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
   PubMed     Abstract available
   
   
   
5. ATREYA R, Neurath MF
   Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
   Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
   PubMed    
   
   
   August 2023
6. SENIOR K
   Surgery in Crohn's disease: patients need MDT-led holistic care.
   Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
   PubMed    
   
   
   
7. SHIN A
   Psychological therapies in inflammatory bowel disease.
   Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
   PubMed    
   
   
   
8. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
   Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
   Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
   PubMed     Abstract available
   
   
   July 2023
9. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
   Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
   Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
   PubMed     Abstract available
   
   
   May 2023
10. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    PubMed    
    
    
    
11. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    PubMed    
    
    
    
12. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    PubMed    
    
    
    
13. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    PubMed    
    
    
    
14. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    PubMed    
    
    
    
15. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    PubMed    
    
    
    
16. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    PubMed    
    
    
    April 2023
17. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    PubMed     Abstract available
    
    
    March 2023
18. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    PubMed     Abstract available
    
    
    
19. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    PubMed    
    
    
    
20. BURISCH J, Zhao M, Odes S, De Cruz P, et al
    The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
    PubMed     Abstract available
    
    
    February 2023
21. OTTEN AT, Bourgonje AR, Visschedijk MC
    Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:99-100.
    PubMed    
    
    
    
22. FEAGAN BG, Sands BE, Sandborn WJ, Germinaro M, et al
    Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(22)00427.
    PubMed     Abstract available
    
    
    
23. VERMEIRE S
    Combination biologic therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(23)00008.
    PubMed    
    
    
    January 2023
24. DREESEN E, Verstockt B
    A personalised taper-to-target strategy with adalimumab in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(23)00009.
    PubMed    
    
    
    
25. VAN LINSCHOTEN RCA, Jansen FM, Pauwels RWM, Smits LJT, et al
    Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(22)00434.
    PubMed     Abstract available
    
    
    
26. LOUIS E, Resche-Rigon M, Laharie D, Satsangi J, et al
    Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00385.
    PubMed     Abstract available
    
    
    
27. FREDERICKS E
    Treatment withdrawal in Crohn's disease: slowly becoming clearer.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00405.
    PubMed    
    
    
    
28. KAMMERMEIER J, Lamb CA, Jones KDJ, Anderson CA, et al
    Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutri
    Lancet Gastroenterol Hepatol. 2023 Jan 9:S2468-1253(22)00337.
    PubMed     Abstract available
    
    
    
29. THORLEY J
    Severine Vermeire: advancing patient-centred research in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:17.
    PubMed    
    
    
    
30. SANDBORN WJ, Panes J, Danese S, Sharafali Z, et al
    Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2023;8:43-55.
    PubMed     Abstract available
    
    
    December 2022
31. LIU Z, Le K, Zhou X, Alexander JL, et al
    Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a p
    Lancet Gastroenterol Hepatol. 2022 Dec 5:S2468-1253(22)00389.
    PubMed     Abstract available
    
    
    
32. ALLEGRETTI JR
    Should faecal microbiota transplantation be used earlier in the treatment framework?
    Lancet Gastroenterol Hepatol. 2022;7:1062-1063.
    PubMed    
    
    
    November 2022
33. NOOR NM, Siegel C
    Partially randomised, patient preference trials for inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022;7:981-983.
    PubMed    
    
    
    October 2022
34. ATIA O, Shavit-Brunschwig Z, Mould DR, Stein R, et al
    Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00307.
    PubMed     Abstract available
    
    
    
35. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00340.
    PubMed    
    
    
    September 2022
36. SELIM R, Wellens J, Brann S, Marlow L, et al
    Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
    Lancet Gastroenterol Hepatol. 2022 Sep 21. pii: S2468-1253(22)00302.
    PubMed    
    
    
    
37. ALEXANDER JL, Liu Z, Munoz Sandoval D, Reynolds C, et al
    COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Sep 8. pii: S2468-1253(22)00274.
    PubMed     Abstract available
    
    
    
38. VERMEIRE S, Sands BE, Tilg H, Tulassay Z, et al
    ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00233.
    PubMed     Abstract available
    
    
    
39. ATREYA R, Neurath MF
    Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00249.
    PubMed    
    
    
    August 2022
40. TIAN H, Zhang S, Qin H, Li N, et al
    Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China.
    Lancet Gastroenterol Hepatol. 2022;7:702-703.
    PubMed    
    
    
    July 2022
41. ANANTHAKRISHNAN AN, Kaplan GG, Bernstein CN, Burke KE, et al
    Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
    Lancet Gastroenterol Hepatol. 2022;7:666-678.
    PubMed     Abstract available
    
    
    
42. MEIMA-VAN PRAAG EM, van Rijn KL, Wasmann KATGM, Snijder HJ, et al
    Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:617-626.
    PubMed     Abstract available
    
    
    June 2022
43. WATERMEYER G, Awuku Y, Fredericks E, Epstein D, et al
    Challenges in the management of inflammatory bowel disease in sub-Saharan Africa.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00048.
    PubMed     Abstract available
    
    
    
44. WATERMEYER G, Katsidzira L, Setshedi M, Devani S, et al
    Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00047.
    PubMed     Abstract available
    
    
    
45. ROSEIRA J, Estevinho MM, Bernardo S, Sousa P, et al
    Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503.
    PubMed    
    
    
    
46. GENERE JR, Deepak P, Kochhar GS
    Reframing self-expandable metal stents for Crohn's strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503-504.
    PubMed    
    
    
    
47. GELDOF J, Iqbal N, LeBlanc JF, Anandabaskaran S, et al
    Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
    Lancet Gastroenterol Hepatol. 2022;7:576-584.
    PubMed     Abstract available
    
    
    May 2022
48. PARIGI TL, D'Amico F, Abreu MT, Rubin DT, et al
    Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Lancet Gastroenterol Hepatol. 2022;7:390-391.
    PubMed    
    
    
    
49. THE LANCET GASTROENTEROLOGY HE
    Opacity over live vaccines in infants exposed to infliximab.
    Lancet Gastroenterol Hepatol. 2022;7:379.
    PubMed    
    
    
    April 2022
50. WELLENS J, Brann S, Adams A, Marlow L, et al
    Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Apr 6. pii: S2468-1253(22)00120.
    PubMed    
    
    
    
51. HAIFER C, Paramsothy S, Kaakoush NO, Leong RW, et al
    Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2022;7:286-287.
    PubMed    
    
    
    
52. YUAN TY, Rajesh R, Tan M
    Oral faecal microbiota transplantation in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022;7:286.
    PubMed    
    
    
    
53. UNGARO RC, Colombel JF
    Treat to target with ustekinumab for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:276-277.
    PubMed    
    
    
    
54. DANESE S, Vermeire S, D'Haens G, Panes J, et al
    Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Lancet Gastroenterol Hepatol. 2022;7:294-306.
    PubMed     Abstract available
    
    
    
55. LORAS C, Andujar X, Gornals JB, Sanchiz V, et al
    Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:332-341.
    PubMed     Abstract available
    
    
    
56. GOREN I, Rieder F
    Endoscopic interventions for stricturing Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:279-280.
    PubMed    
    
    
    
57. SCHULBERG JD, Wright EK, Holt BA, Hamilton AL, et al
    Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2022;7:318-331.
    PubMed     Abstract available
    
    
    March 2022
58. MATSUOKA K, Watanabe M, Ohmori T, Nakajima K, et al
    AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2022 Mar 30. pii: S2468-1253(22)00022.
    PubMed     Abstract available
    
    
    
59. KOTZE PG, Heuthorst L, Lightner AL, Damiao AOMC, et al
    New insights on the surgical management of ulcerative colitis in the 21st century.
    Lancet Gastroenterol Hepatol. 2022 Mar 29. pii: S2468-1253(22)00001.
    PubMed     Abstract available
    
    
    February 2022
60. KUENZIG ME, Widdifield J, Bernatsky S, Kaplan GG, et al
    Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
    Lancet Gastroenterol Hepatol. 2022 Feb 22. pii: S2468-1253(22)00054.
    PubMed    
    
    
    
61. ALEXANDER JL, Kennedy NA, Ibraheim H, Anandabaskaran S, et al
    COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Feb 3. pii: S2468-1253(22)00005.
    PubMed     Abstract available
    
    
    
62. PAPAMICHAEL K, Afif W, Drobne D, Dubinsky MC, et al
    Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Lancet Gastroenterol Hepatol. 2022;7:171-185.
    PubMed     Abstract available
    
    
    
63. OZPOLAT HT, Baran B, Akyuz F
    Septic arthritis: a presentation of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:196.
    PubMed    
    
    
    January 2022
64. GUILLO L, Abreu M, Panaccione R, Sandborn WJ, et al
    Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
    Lancet Gastroenterol Hepatol. 2022 Jan 17. pii: S2468-1253(21)00297.
    PubMed     Abstract available
    
    
    
65. SASSON AN
    A whole-food exclusion diet as monotherapy for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:6-7.
    PubMed    
    
    
    
66. SHEN B, Kochhar GS, Rubin DT, Kane SV, et al
    Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2022;7:69-95.
    PubMed     Abstract available
    
    
    
67. YANAI H, Levine A, Hirsch A, Boneh RS, et al
    The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:49-59.
    PubMed     Abstract available
    
    
    December 2021
68. HAIFER C, Paramsothy S, Kaakoush NO, Saikal A, et al
    Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00400.
    PubMed     Abstract available
    
    
    
69. FISCHER M, Khoruts A
    Oral lyophilised microbiota for the treatment of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00433.
    PubMed    
    
    
    
70. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    PubMed    
    
    
    
71. SO D, Tuck CJ
    Plant-based diets in gastrointestinal disorders: something, nothing, or everything?
    Lancet Gastroenterol Hepatol. 2021;6:992.
    PubMed    
    
    
    
72. THOMAS H
    UEG Week Virtual 2021.
    Lancet Gastroenterol Hepatol. 2021;6:990.
    PubMed    
    
    
    
73. SINGH S, Murad MH, Fumery M, Sedano R, et al
    Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021;6:1002-1014.
    PubMed     Abstract available
    
    
    November 2021
74. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    PubMed     Abstract available
    
    
    
75. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    PubMed    
    
    
    
76. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    PubMed     Abstract available
    
    
    
77. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed     Abstract available
    
    
    
78. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed     Abstract available
    
    
    
79. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed     Abstract available
    
    
    
80. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed     Abstract available
    
    
    
81. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed    
    
    
    
82. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed    
    
    
    
83. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    PubMed    
    
    
    October 2021
84. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    PubMed    
    
    
    
85. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    PubMed    
    
    
    
86. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    PubMed     Abstract available
    
    
    
87. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
    Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2021;6:816-825.
    PubMed     Abstract available
    
    
    September 2021
88. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
    Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:691-692.
    PubMed    
    
    
    
89. SYAL G, Fleshner PR, Melmed GY
    Endoscopic evaluation after surgery in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:690-691.
    PubMed    
    
    
    
90. KOBAYASHI T
    Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:688.
    PubMed    
    
    
    
91. TAN M, Ng V, Lim CT, Leow WQ, et al
    Stringent criteria for withdrawal of biologics in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021;6:687-688.
    PubMed    
    
    
    August 2021
92. FIORINO G, Allocca M, Danese S
    Adalimumab biosimilar in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
    PubMed    
    
    
    
93. GEYL S, Guillo L, Laurent V, D'Amico F, et al
    Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2021;6:659-667.
    PubMed     Abstract available
    
    
    July 2021
94. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    PubMed     Abstract available
    
    
    
95. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    PubMed    
    
    
    
96. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    PubMed    
    
    
    
97. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    PubMed    
    
    
    June 2021
98. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed     Abstract available
    
    
    May 2021
99. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    PubMed    
    
    
    
100. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
     Defining difficult-to-treat inflammatory bowel disease: why and how.
     Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
     PubMed    
     
     
     
101. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
     Breaking the therapeutic ceiling in drug development in ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
     PubMed     Abstract available
     
     
     
102. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
     The impact of SARS-CoV-2 variants on IBD management.
     Lancet Gastroenterol Hepatol. 2021;6:343-344.
     PubMed    
     
     
     April 2021
103. UNGAR B
     Infliximab discontinuation in patients with ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
     PubMed    
     
     
     
104. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
     Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
     Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
     PubMed     Abstract available
     
     
     
105. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
     Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
     Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
     PubMed     Abstract available
     
     
     March 2021
106. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
     Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
     Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
     PubMed     Abstract available
     
     
     
107. KEEFER L
     What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
     Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
     PubMed    
     
     
     
108. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
     The ileoanal pouch: the next frontier in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021;6:164-165.
     PubMed    
     
     
     
109. JENA A, Jha DK, Sharma V
     Distinguishing intestinal tuberculosis from Crohn's disease.
     Lancet Gastroenterol Hepatol. 2021;6:159.
     PubMed    
     
     
     
110. BANERJEE R, Pal P
     Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
     Lancet Gastroenterol Hepatol. 2021;6:159-160.
     PubMed    
     
     
     February 2021
111. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
     Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
     Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
     PubMed     Abstract available
     
     
     
112. SHEN B
     Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
     Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
     PubMed    
     
     
     
113. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
     From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
     Lancet Gastroenterol Hepatol. 2021;6:88-89.
     PubMed    
     
     
     January 2021
114. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
     SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
     Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
     PubMed     Abstract available
     
     
     December 2020
115. NG SC, Mak JWY, Pal P, Banerjee R, et al
     Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
     Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
     PubMed     Abstract available
     
     
     
116. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
     Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
     Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
     PubMed     Abstract available
     
     
     
117. STRID H
     Prevalence of IBS-type symptoms in IBD.
     Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
     PubMed    
     
     
     November 2020
118. AZIZ I, Simren M
     The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
     Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
     PubMed     Abstract available
     
     
     October 2020
119. MA C, Panaccione R
     Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
     PubMed    
     
     
     
120. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
     Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
     Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
     PubMed     Abstract available
     
     
     
121. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
     IBD in the COVID-19 era: the value of international collaboration.
     Lancet Gastroenterol Hepatol. 2020;5:887-888.
     PubMed    
     
     
     
122. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
     Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
     Lancet Gastroenterol Hepatol. 2020;5:900-907.
     PubMed     Abstract available
     
     
     
123. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
     Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
     Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
     PubMed     Abstract available
     
     
     May 2020
124. LOUGHMAN A, Staudacher HM
     Treating the individual with diet: is gut microbiome testing the answer?
     Lancet Gastroenterol Hepatol. 2020;5:437.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.